Level 1 — Sub-perceptual 🍄 B+ ⚖️ 0.1g–0.15g 📍 Home, daily tracking

Microdosing psilocybin for fibromyalgia — 4 months of tracking

I have fibromyalgia and tracked 4 months of microdosing with pain diaries, sleep logs, and medication use. Here's what the data shows.

microdosing chronic pain fibromyalgia tracking therapeutic
About this report: Therapeutic. Presented for educational harm-reduction purposes. Details have been edited for clarity and privacy.

I was diagnosed with fibromyalgia seven years ago. I've tried most of the standard treatments — pregabalin, duloxetine, physical therapy, low-dose naltrexone. All partial at best. I'm a biologist and I track everything obsessively, so when I started microdosing I did it with pain diaries, sleep logs, and daily mood ratings.

Protocol: 0.1–0.15g dried B+ on a Fadiman protocol (dose day, rest, rest, repeat). I weigh on a milligram scale. Four months of data, roughly 40 dose days total.

What the data showed:

  • Pain: Mean daily pain rating dropped from 5.2 to 4.1 (10-point scale). Not dramatic, but consistent and meaningful for quality of life. The variance also decreased — fewer 8/9 days.
  • Sleep: Sleep quality improved on post-dose days. The third day of each cycle (day before the next dose) often had my worst sleep. Unclear if this is real or tracking artifact.
  • Mood and energy: Most consistently positive effect. Emotional reactivity to pain decreased — the suffering component of pain, separate from intensity, seemed reduced.
  • Medication use: PRN pain medication use dropped by roughly 30% over the 4 months.

Limitations I'm honest about: This is one person with no control condition. Placebo effect, seasonal variation, regression to the mean — all could explain these results. I have not done a blinded self-experiment. What I can say is that the changes felt qualitatively different from placebo effects I've experienced before, and they were consistent across 4 months rather than fading.

I'm continuing. I'm not stopping my other treatments. And I've started logging more rigorously to look for dose-response patterns.

Note on chronic pain and psilocybin: The mechanism for pain effects is not fully understood. 5-HT2A receptor distribution in pain-processing circuits and psilocybin's anti-inflammatory properties may both be relevant. Clinical research on psilocybin for chronic pain is early-stage but ongoing.

More Experience Reports